Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24339322 | 0.81 | MAPK1 (0.47) | ROCK2ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL30038884 | 0.81 | MAPK1 (0.47) | ROCK2ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL29390014 | 0.80 | KDM4E (0.42) | ROCK2PIM1GSK3BMAPTNPC1 | |
| SCHEMBL17443544 | 0.80 | KDM4E (0.42) | ROCK2PIM1GSK3BMAPTNPC1 | |
| SCHEMBL17439546 | 0.78 | CHEK1 (0.44) | ROCK2PIM1ALDH1A1MAPTRAB9A | |
| SCHEMBL29950421 | 0.78 | CHEK1 (0.44) | ROCK2PIM1ALDH1A1MAPTRAB9A | |
| SCHEMBL19275664 | 0.75 | CHEK1 (0.40) | ROCK2ALDH1A1MAPTRAB9AHPGD | |
| SCHEMBL31738598 | 0.74 | MAOB (0.62) | ROCK2PIM1GSK3BALDH1A1MAPT | |
| SCHEMBL4154121 | 0.74 | MAOB (0.62) | ROCK2PIM1GSK3BALDH1A1MAPT | |
| SCHEMBL18372731 | 0.74 | L3MBTL1 (0.41) | ALDH1A1NPC1RAB9AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526219-B1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2021-12-15 | — | — | EP | disclosed |
| US-10391099-B2 | Method of treating psoriatic arthritis, psoriasis, and chronic obstructive pulmonary disease with a novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| US-20170065603-A1 | Novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2017-03-09 | — | — | US | disclosed |
| US-20160016938-A1 | Novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170065603-A1 | Novel 2,5-substituted pyrimidines | PDE4B, PDE4A, PDE12 | ROCK2 2606/4885PIM1 4418/4885GSK3B 3260/4885 |
| US-20160016938-A1 | Novel 2,5-substituted pyrimidines | PDE4B, PDE4A, PDE12 | ROCK2 2606/4885PIM1 4418/4885GSK3B 3260/4885 |
| US-10391099-B2 | Method of treating psoriatic arthritis, psoriasis, and chronic obstructive pulmonary disease with a novel 2,5-substituted pyrimidines | PDE4B, PDE4A, PDE12 | ROCK2 1281/4885PIM1 3374/4885GSK3B 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.